# US Patent 9,701,712: Etelcalcetide Claims, Patent Scope, Exclusivity and Generic-Entry Risk
US Patent 9,701,712 protects salts of a defined class of arginine-rich disulfide-linked peptides, including the active pharmaceutical ingredient in Parsabiv, etelcalcetide hydrochloride. The patent covers composition-of-matter claims, N- and C-terminal modifications, hydrochloride salts, pharmaceutical compositions, and intravenous treatment of secondary hyperparathyroidism in chronic kidney disease. Its strongest claims are the species claims directed to Ac-c(C)arrrar-NH2 and the corresponding hydrochloride salt. [1]
What drug does US Patent 9,701,712 protect?
US 9,701,712 is directed to etelcalcetide-related peptide compounds. Etelcalcetide is an eight-amino-acid peptide incorporating a disulfide-linked L-cysteine residue and a D-amino-acid sequence. Amgen markets etelcalcetide hydrochloride in the United States as Parsabiv, an intravenous calcimimetic for secondary hyperparathyroidism in adults with chronic kidney disease receiving hemodialysis. [2]
The patent’s claim 8 species, Ac-c(C)arrrar-NH2, corresponds to the protected etelcalcetide structure when the notation is read as an acetylated peptide containing a cysteine disulfide-linked to an additional cysteine and ending in an amide. Claim 9 narrows that species to the hydrochloride salt.
Core structural elements
| Element |
Patent requirement |
| Peptide length |
8 to 11 amino acids for claim 1 |
| Core sequence |
X1-X2-X3-X4-X5-X6-X7 |
| X1 |
L-cysteine or D-cysteine |
| X2 |
D-alanine or D-arginine |
| X3 |
D-arginine |
| X4 |
D-alanine or D-arginine |
| X5 |
D-arginine |
| X6 |
D-alanine |
| X7 |
D-arginine |
| N-terminus |
Optional acetylation |
| C-terminus |
Optional amidation |
| Cysteine linkage |
Disulfide bond to L- or D-cysteine |
| Salt |
Pharmaceutically acceptable salt; hydrochloride expressly claimed |
| Therapeutic use |
Secondary hyperparathyroidism |
| Administration |
Intravenous administration expressly claimed |
How broad are the composition claims in US 9,701,712?
Claim 1 is a genus claim. It covers a pharmaceutically acceptable salt of any peptide that satisfies the specified seven-residue sequence pattern and has a total length of 8 to 11 amino acids.
The sequence-variable positions are X1, X2 and X4:
- X1 has two alternatives: L-cysteine or D-cysteine.
- X2 has two alternatives: D-alanine or D-arginine.
- X4 has two alternatives: D-alanine or D-arginine.
On a simple sequence basis, those alternatives produce eight expressly specified sequence combinations. The claim also covers peptide variants within the 8-to-11-residue length range, subject to the requirement that the peptide comprise the claimed sequence.
The claim is materially broader than the named species in claim 8 because it does not require, on its face, all of the following:
- the specific Ac-c(C)arrrar-NH2 structure;
- the exact cysteine stereochemistry used in etelcalcetide;
- both terminal modifications;
- a hydrochloride salt;
- intravenous administration; or
- treatment of chronic kidney disease.
Claim-construction issues
The phrase "comprises the amino acid sequence" makes claim 1 an open-ended composition claim. A peptide may contain the claimed sequence and additional residues, provided it remains within the 8-to-11-amino-acid length limitation. The claim therefore reaches more than the exact eight-residue etelcalcetide structure.
The phrase "pharmaceutically acceptable salt" is also broad. Claim 1 is not limited to hydrochloride. Claim 11 separately identifies the hydrochloride salt, but a salt falling within claim 1 could include another pharmaceutically acceptable counterion if it satisfies the remaining structural limitations.
Claims 5 and 6 introduce a disulfide-linked cysteine. Those claims are important because the additional cysteine accounts for the eight-residue structure associated with etelcalcetide. A competing peptide that uses a non-cysteine bridge, a different linkage, or a chemically distinct cyclization strategy would have a stronger non-infringement position, although the analysis would depend on the patent’s written description and prosecution history.
What are the claims of US Patent 9,701,712?
Composition-of-matter claims
Claims 1 through 11 establish the principal chemical protection.
- Claim 1 covers the broader salt genus.
- Claims 2 and 7 cover N-terminal acetylation.
- Claim 3 covers C-terminal amidation.
- Claim 4 covers both acetylation and amidation.
- Claims 5 and 6 cover disulfide conjugation to L- or D-cysteine.
- Claim 8 covers the specific Ac-c(C)arrrar-NH2 peptide.
- Claim 9 narrows claim 8 to the hydrochloride salt.
- Claim 10 covers a pharmaceutical composition containing the claim 8 salt.
- Claim 11 narrows claim 1 to the hydrochloride salt.
Claim 7 substantially overlaps claim 2. Because it repeats the N-terminal acetylation limitation without adding a distinct limitation, it appears to provide little incremental scope over claim 2.
Method-of-treatment claims
Claims 12 through 17 cover treatment of secondary hyperparathyroidism:
- Claim 12 applies to salts within claim 1.
- Claim 13 limits the patient population to subjects with chronic kidney disease.
- Claim 14 limits administration to intravenous delivery.
- Claim 15 applies the treatment method to the specific claim 8 salt.
- Claims 16 and 17 add chronic kidney disease and intravenous administration, respectively.
The method claims are narrower than the composition claims in patient and use context. They can remain commercially relevant because Parsabiv is administered intravenously to hemodialysis patients with chronic kidney disease, matching the label’s approved use. [2]
What is the strongest patent protection for etelcalcetide?
The strongest protection is the combination of claims 8, 9 and 10.
| Claim |
Commercial relevance |
Relative strength |
| Claim 1 |
Broad salt genus and peptide sequence class |
Broad, but exposed to validity and claim-construction challenges |
| Claim 4 |
Acetylated and amidated peptide |
Intermediate |
| Claims 5-6 |
Disulfide-linked cysteine variants |
Intermediate to strong if the accused structure uses the claimed linkage |
| Claim 8 |
Specific etelcalcetide-related peptide |
Strong composition claim |
| Claim 9 |
Specific hydrochloride salt |
Strongest product-specific claim |
| Claim 10 |
Pharmaceutical composition containing claim 8 salt |
Strong product-formulation claim |
| Claims 12-17 |
SHPT treatment, CKD, intravenous administration |
Useful for labeled-use enforcement, but narrower |
A generic product containing the same etelcalcetide hydrochloride active ingredient would face the most direct risk under claims 8 and 9. A product using the same peptide but a different salt could still implicate claim 8 if claim 8 is construed to cover the peptide salt broadly, while claim 9 would be limited to hydrochloride.
When does US Patent 9,701,712 expire?
The patent was issued on July 11, 2017. Public patent records identify a February 12, 2013 priority date and a February 14, 2014 nonprovisional filing date. The nominal United States patent-term endpoint is therefore February 14, 2034, before accounting for patent-term adjustment, terminal disclaimers, patent-term extension, or other term-specific corrections. [1]
For commercial planning, the relevant date is the enforceable term endpoint recorded by the USPTO and reflected in current FDA Orange Book patent information, not the issue date. The patent’s term is materially longer than Parsabiv’s FDA regulatory exclusivity.
FDA exclusivity timeline
| Event |
Date |
| Parsabiv FDA approval |
November 17, 2017 |
| Likely NCE exclusivity period |
Through November 17, 2022 |
| US 9,701,712 issue |
July 11, 2017 |
| Nominal patent-term endpoint based on cited filing date |
February 14, 2034 |
The five-year new chemical entity exclusivity period blocked submission of an ANDA or 505(b)(2) application referencing etelcalcetide during the statutory exclusivity period, subject to the Hatch-Waxman framework. Patent protection extends beyond that regulatory period. [2, 3]
What is the Orange Book status of US Patent 9,701,712?
Parsabiv is an FDA-approved small-molecule/peptide drug product rather than a biologic licensed through a BLA. Its relevant patent information is therefore handled through the Orange Book framework, not the Purple Book biosimilar framework. [3, 4]
The commercial significance of an Orange Book listing depends on:
- Whether the patent is listed against the approved Parsabiv product.
- Whether the listed claims cover the active ingredient, formulation, or approved method of use.
- Whether the listed use code corresponds to the proposed generic label.
- Whether an ANDA applicant submits a Paragraph IV certification.
- Whether Amgen files an infringement action within the statutory period after receiving notice.
Claims 8 and 9 are product-focused. Claims 12 through 17 are method claims and would generally be relevant only if the listed method corresponds to an approved use and the proposed generic labeling or actual conduct falls within the claimed method.
What Paragraph IV challenges and generic-entry risks exist?
A generic applicant seeking approval of an etelcalcetide hydrochloride product could challenge the patent through a Paragraph IV certification alleging that the patent is invalid, unenforceable or not infringed. The likely challenge points would differ by claim.
Likely composition-claim challenges
For claims 8 and 9, the principal issues would include:
- anticipation by an earlier disclosure of the exact peptide or salt;
- obviousness based on known calcimimetic peptides and peptide-salt chemistry;
- written-description support for the full claimed salt and peptide scope;
- enablement across the claimed sequence and salt genus;
- claim construction of the disulfide-linked cysteine notation;
- whether the proposed product contains the claimed stereochemistry and terminal groups.
Likely method-claim challenges
For claims 12 through 17, a generic applicant may argue:
- non-infringement based on a skinny label;
- lack of induced infringement if the approved labeling omits the patented use;
- invalidity based on prior clinical or medical-use disclosures;
- lack of infringement where administration is not intravenous or the patient population differs.
The practical risk is highest for a product that is chemically identical to Parsabiv and labeled for intravenous treatment of SHPT in hemodialysis patients. A non-identical formulation, alternate route of administration or materially different indication could reduce method-claim exposure but would not necessarily avoid the composition claims.
Is biosimilar risk relevant to etelcalcetide?
Biosimilar risk is limited because etelcalcetide hydrochloride is regulated as a drug product under the NDA pathway rather than as a biologic under the BLA pathway. A competitor would generally pursue an ANDA or potentially a 505(b)(2) application, not a biosimilar application under the abbreviated biologics pathway. [3, 4]
The principal competitive threat is therefore a generic or follow-on etelcalcetide product. The complexity of peptide synthesis, disulfide control, stereochemical purity, analytical characterization and sterile intravenous manufacturing may make development more difficult than ordinary small-molecule generic production. Those manufacturing barriers do not eliminate an ANDA challenge if the applicant can establish pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable FDA requirements.
What formulations and manufacturing processes are protected?
US 9,701,712 is not principally a formulation patent. Claim 10 broadly covers a pharmaceutical composition containing the claim 8 salt, but the supplied claims do not recite:
- a specific buffer;
- pH range;
- excipient;
- concentration;
- container;
- lyophilized presentation;
- stability profile;
- delivery device; or
- manufacturing process.
The patent’s principal barrier is the active peptide and its salt form. A separate patent family would be needed to establish protection for a particular Parsabiv formulation, manufacturing process, impurity profile or container closure system. The absence of those limitations in the supplied claims means that a competitor cannot avoid the patent merely by changing excipients if it still uses the claimed peptide salt.
Which companies compete with Parsabiv?
Parsabiv competes primarily with other calcimimetics and established treatments for secondary hyperparathyroidism.
| Product |
Active ingredient |
Company or market status |
Competitive relationship |
| Parsabiv |
Etelcalcetide |
Amgen |
Intravenous calcimimetic |
| Sensipar |
Cinacalcet |
Amgen-originated product; generic versions available |
Oral calcimimetic |
| Generic cinacalcet |
Cinacalcet hydrochloride |
Multiple generic manufacturers |
Price pressure and substitution |
| Vitamin D analogs |
Various |
Multiple manufacturers |
Alternative SHPT therapy |
| Phosphate binders |
Various |
Multiple manufacturers |
Adjunctive treatment, not direct substitutes |
Etelcalcetide’s patent estate protects a specific intravenous peptide product, while cinacalcet faces a mature generic market. The competitive distinction is clinically and commercially relevant: generic cinacalcet creates pricing pressure, but it does not directly practice etelcalcetide composition claims.
What patent litigation affects US 9,701,712?
The supplied record establishes the patent’s issued claims but does not establish a specific final infringement judgment, settlement or Paragraph IV resolution for US 9,701,712. The litigation risk analysis is therefore claim-driven:
- direct etelcalcetide hydrochloride ANDA litigation would center on claims 8 and 9;
- method-of-use litigation would center on claims 12 through 17;
- a settlement could permit a licensed generic entry date before the nominal patent endpoint;
- a court judgment could narrow or invalidate individual claims without eliminating the entire patent.
A complete litigation conclusion cannot be drawn solely from the claim text. Patent-family prosecution history, Orange Book listing records, FDA Paragraph IV notices and PACER docket information control the current status.
How strong is the US 9,701,712 patent estate?
The patent is commercially strongest as a product patent for etelcalcetide hydrochloride. Its main advantages are:
- direct coverage of the named peptide species;
- express hydrochloride-salt protection;
- composition coverage independent of the treatment indication;
- alignment with Parsabiv’s intravenous administration and SHPT indication;
- a nominal term extending into 2034.
Its principal vulnerabilities are:
- potential prior-art attacks against the peptide sequence or salt;
- claim-construction disputes involving the notation and disulfide-linked cysteine;
- narrower scope for the method claims;
- possible design-around strategies involving a different peptide, stereochemistry, linkage or salt;
- the absence, in the supplied claims, of detailed formulation and manufacturing limitations.
Key Takeaways
- US 9,701,712 protects etelcalcetide-related peptide salts, including the hydrochloride salt associated with Parsabiv.
- Claims 8 and 9 are the most direct product claims against an etelcalcetide hydrochloride generic.
- Claim 1 is broader and covers a genus of 8-to-11-residue salts with defined D-amino-acid sequence elements.
- Claims 12 through 17 protect treatment of SHPT, particularly in chronic kidney disease patients receiving intravenous therapy.
- Parsabiv received FDA approval on November 17, 2017, with regulatory exclusivity ending before the patent’s nominal February 14, 2034 term endpoint.
- Generic risk is an ANDA and Paragraph IV issue, not primarily a biosimilar issue.
- The supplied claims do not establish detailed protection for excipients, buffers, containers or manufacturing processes.
- A current freedom-to-operate conclusion requires analysis of the full patent family, Orange Book listings, prosecution history and any Paragraph IV litigation or settlement records.
FAQs
What is the active ingredient protected by US 9,701,712?
The patent protects etelcalcetide-related peptide salts, including the hydrochloride salt of the acetylated, amidated, disulfide-linked peptide represented as Ac-c(C)arrrar-NH2.
Does US 9,701,712 cover free-base etelcalcetide?
The independent composition claim requires a pharmaceutically acceptable salt. The supplied claims therefore do not expressly cover the free-base form as such.
Can a different salt avoid US 9,701,712?
A different pharmaceutically acceptable salt may remain within claim 1, which is not limited to hydrochloride. It may avoid claim 9 if claim 9 is construed as limited to the hydrochloride salt, but composition and infringement analysis would depend on the precise structure and claim construction.
Is Parsabiv protected by a biologic patent pathway?
No. Parsabiv is handled through the NDA and Orange Book framework rather than the BLA and Purple Book biosimilar framework.
What is the likely generic launch strategy for etelcalcetide?
The most direct strategy would involve an ANDA with a Paragraph IV certification against relevant listed patents, followed by potential Hatch-Waxman litigation. A non-infringing formulation would not avoid claims 8 and 9 if it contains the same protected etelcalcetide hydrochloride active ingredient.
References
- United States Patent and Trademark Office. (2017). U.S. Patent No. 9,701,712, Peptide compounds.
- U.S. Food and Drug Administration. (2017). Parsabiv (etelcalcetide) injection: Prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (n.d.). Purple Book: Lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations.
